πŸ‡ΊπŸ‡Έ FDA
Patent

US 9789184

Anti-EGFR antibodies and uses thereof

granted A61KA61K2039/505A61K2039/507

Quick answer

US patent 9789184 (Anti-EGFR antibodies and uses thereof) held by REGENERON PHARMACEUTICALS, INC. expires Mon Oct 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Oct 17 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K2039/505, A61K2039/507, A61K39/3955, A61K39/39558